Quick Answer
Sagimet Biosciences Inc. reported Total Revenue of $2.00 million for fiscal year 2023.
Sagimet Biosciences Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | — | — | $2.00M | — | — |
| Revenue (ASC 606) | — | — | $2.00M | — | — |
| Net Income | -$51.04M -12.0% |
-$45.57M -63.5% |
-$27.88M +8.6% |
-$30.50M | — |
| Diluted EPS | -$1.58 -9.0% |
-$1.45 +45.5% |
-$2.66 +98.4% |
-$165.20 | — |
| Total Assets | $116.48M -27.3% |
$160.26M +65.7% |
$96.72M +192.8% |
$33.03M | — |
| Cash and Equivalents | $35.02M -53.8% |
$75.84M +0.9% |
$75.14M +47456.3% |
$158.0K | — |
| Stockholders Equity | $111.38M -28.5% |
$155.81M +71.1% |
$91.06M +148.7% |
-$186.95M -18.1% |
-$158.26M |
| R&D Expense | $39.05M +1.6% |
$38.44M +94.4% |
$19.78M -20.6% |
$24.92M | — |
| Operating Income | -$56.89M -4.5% |
-$54.45M -77.1% |
-$30.74M +1.0% |
-$31.05M | — |
| Shares Outstanding | — | — | 0 -100.0% |
185,084 | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2023 | $2.00M | — | +0.0% |
| Revenue (ASC 606) | September 30, 2023 | $2.00M | — | +0.0% |
| Net Income | September 30, 2025 | -$12.91M | +11.7% | -24.3% |
| Diluted EPS | September 30, 2025 | -$0.40 | +11.1% | -25.0% |
| Total Assets | September 30, 2025 | $128.40M | -26.5% | -6.6% |
| Cash and Equivalents | September 30, 2025 | $32.50M | -57.8% | -23.2% |
| Stockholders Equity | September 30, 2025 | $119.25M | -30.1% | -8.4% |
| R&D Expense | September 30, 2025 | $9.73M | -23.1% | +34.2% |
| Operating Income | September 30, 2025 | -$14.33M | +15.2% | -20.2% |
| Shares Outstanding | September 30, 2023 | 0 | — | -100.0% |
- Sagimet Biosciences Inc. reported Total Revenue of $2.00 million for fiscal year 2023.
- Sagimet Biosciences Inc. reported Revenue (ASC 606) of $2.00 million for fiscal year 2023.
- Sagimet Biosciences Inc. reported Net Income of -$51.04 million for fiscal year 2025.
- Sagimet Biosciences Inc. showed a decrease of -12.0% in Net Income compared to the prior fiscal year.
- Sagimet Biosciences Inc. reported Diluted EPS of $1.58 per share (loss) for fiscal year 2025.
- Sagimet Biosciences Inc. showed a decrease of -9.0% in Diluted EPS compared to the prior fiscal year.
- Sagimet Biosciences Inc. reported Total Assets of $116.48 million for fiscal year 2025.
- Sagimet Biosciences Inc. showed a decrease of -27.3% in Total Assets compared to the prior fiscal year.
- Sagimet Biosciences Inc. reported Cash and Equivalents of $35.02 million for fiscal year 2025.
- Sagimet Biosciences Inc. showed a decrease of -53.8% in Cash and Equivalents compared to the prior fiscal year.
- Sagimet Biosciences Inc. reported Stockholders Equity of $111.38 million for fiscal year 2025.
- Sagimet Biosciences Inc. showed a decrease of -28.5% in Stockholders Equity compared to the prior fiscal year.
- Sagimet Biosciences Inc. reported R&D Expense of $39.05 million for fiscal year 2025.
- Sagimet Biosciences Inc. showed an increase of +1.6% in R&D Expense compared to the prior fiscal year.
- Sagimet Biosciences Inc. reported Operating Income of -$56.89 million for fiscal year 2025.
- Sagimet Biosciences Inc. showed a decrease of -4.5% in Operating Income compared to the prior fiscal year.
- Sagimet Biosciences Inc. reported Shares Outstanding of 0 shares for fiscal year 2023.
- Sagimet Biosciences Inc. showed a decrease of -100.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: